Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

October 22, 2019

Study Completion Date

October 29, 2019

Conditions

Healthy

Interventions

DRUG

CR845 0.5 mcg/kg IV

0.5 mcg/kg IV CR845

DRUG

CR845 3 mcg/kg IV

3 mcg/kg IV CR845

DRUG

Moxifloxacin 400 mg Oral Tablet

400 mg Oral Moxifloxacin

OTHER

Placebo

IV Placebo as a bolus injection

Trial Locations (1)

Cara Therapeutics Study Site, Dallas